" class="no-js "lang="en-US"> Subtle Medical Announces Partnership Expansion With Incepto - Medtech Alert
Saturday, March 22, 2025

Subtle Medical Announces Partnership Expansion With Incepto

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto, a leading platform of artificial intelligence solutions for radiology professionals in Europe, by offering their AI applications, SubtleMR and SubtlePET on Incepto’s platform.

“We are excited to deepen our existing distributor partnership with Incepto and be included on their platform. This expansion will provide their existing customer base with quick access to our AI solutions without the long implementation process or IT hurdles,” says Subtle Medical’s Chief Product Officer, Ajit Shankaranarayanan.

“Today SubtleMR and SubtlePET AI based software products are installed at hundreds of facilities throughout the world making a positive difference everyday in workflow and patient comfort. We could not be more pleased to have our products running on the Incepto platform and providing access to Incepto customers,” said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

Subtle Medical’s suite of clinically validated AI-powered software solutions, SubtleMR™ and SubtlePET™, increase the efficiency of image capture by improving the quality of both accelerated and low dose imaging. Subtle’s solutions are compatible with all scanner models and field strengths so institutions can see the benefit across their entire scanner fleet.

Incepto will be introducing SubtlePET™ and SubtleMR™ on their platform at ECR this week in Vienna, Austria. For more information or our products or partnership, please visit the Subtle Medical booth on-site, booth Expo X2 – #233, or request to meet with us here.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more